BMJ

1. BARANIUK C
   mRNA vaccines are under threat-could cancer vaccines be the answer?
   BMJ. 2026;392:r2449.
   

   >> Share

   
   
2. WISE J
   Covid vaccine hesitancy decreased over time, but mistrust persists in some groups, study suggests.
   BMJ. 2026;392:s67.
   

   >> Share

   
   

   
   J Gen Virol

3. MIMMS JL, Sinnis-Bourozikas A, Felbinger NR, Frumento N, et al
   Antigenicity of key hepatitis C virus E1E2 glycoprotein neutralizing sites is genotype independent.
   J Gen Virol. 2026;107:002201.
   

   >> Share

   
   

   
   J Infect

4. GEERS D, Aguilar-Bretones M, Zaeck LM, Gill PA, et al
   Preferential boosting of SARS-CoV-2 Omicron lineage-specific immune responses by monovalent XBB.1.5 vaccination.
   J Infect. 2026;92:106681.
   

   >> Share

   
   

   
   JAMA

5. RUBIN R
   Nudging Increases Flu Vaccine Uptake.
   JAMA. 2026 Jan 16. doi: 10.1001/jama.2025.23023.
   

   >> Share

   
   
6. FATTAH M, Stoffel LA, Bubar KM, Bents SJ, et al
   Trends in County-Level Childhood Vaccination Exemptions in the US.
   JAMA. 2026 Jan 14:e2524407. doi: 10.1001/jama.2025.24407.
   

   >> Share

   
   
7. MELLO MM, Walensky RP, Osterholm MT, Brennan TA, et al
   Navigating Conflicting Vaccination Recommendations: Guidance for Clinicians.
   JAMA. 2026 Jan 13. doi: 10.1001/jama.2026.0276.
   

   >> Share

   
   

   
   Lancet

8. VAN GEERTRUYDEN JP, Lariviere Y, Zola Matuvanga T, Van Damme P, et al
   Ebola and health-care providers: the case for preventive vaccination.
   Lancet. 2026 Jan 12:S0140-6736(25)02459-6. doi: 10.1016/S0140-6736(25)02459.
   

   >> Share

   
   
9. WHITAKER M, Elliott J, Gerard-Ursin I, Cooke GS, et al
   Profiling vaccine attitudes and subsequent uptake in 1.1 million people in England: a nationwide cohort study.
   Lancet. 2026 Jan 12:S0140-6736(25)01912-9. doi: 10.1016/S0140-6736(25)01912.
   

   >> Share

   
   
10. PALMIERI C, Tafuri S
    Vaccine hesitancy: an evolving challenge.
    Lancet. 2026 Jan 12:S0140-6736(25)02601-7. doi: 10.1016/S0140-6736(25)02601.
    

    >> Share

    
    
11. TURTLE L
    Yellow fever vaccine minimum fractional dosing does not extend to infants.
    Lancet. 2026 Jan 13:S0140-6736(25)02364-5. doi: 10.1016/S0140-6736(25)02364.
    

    >> Share

    
    
12. KIMATHI D, Juan-Giner A, Bob NS, Orindi B, et al
    Low-dose yellow fever vaccination in infants: a randomised, double-blind, non-inferiority trial.
    Lancet. 2026 Jan 13:S0140-6736(25)02069-0. doi: 10.1016/S0140-6736(25)02069.
    

    >> Share

    
    

    
    N Engl J Med

13. CAI M, Xie Y, Al-Aly Z
    2024-2025 Covid-19 Vaccine Outcomes in U.S. Veterans. Reply.
    N Engl J Med. 2026;394:307.
    

    >> Share

    
    
14. YANG C, Tebbutt SJ
    2024-2025 Covid-19 Vaccine Outcomes in U.S. Veterans.
    N Engl J Med. 2026;394:306-307.
    

    >> Share

    
    

    
    Nat Med

15. D'ALISE AM, Willis J, Duzagac F, Hall MJ, et al
    Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial.
    Nat Med. 2026 Jan 16. doi: 10.1038/s41591-025-04182.
    

    >> Share

    
    

    
    PLoS Med

16. STANTON TD, Keegan SP, Abdulahi JA, Amulele AV, et al
    Distribution of capsule and O types in Klebsiella pneumoniae causing neonatal sepsis in Africa and South Asia: A meta-analysis of genome-predicted serotype prevalence to inform potential vaccine coverage.
    PLoS Med. 2026;23:e1004879.
    

    >> Share

    
    

    
    PLoS One

17. CUI L, Tong N, Hou S, Yu C, et al
    Adverse events following Synflorix vaccination reported to the Vaccine Adverse Event Reporting System (VAERS), 2010-2024.
    PLoS One. 2026;21:e0338640.
    

    >> Share

    
    
18. ZENG Z, Sathasivam S, Xin J, Zhao H, et al
    Public participation in healthcare safety: A tripartite evolutionary game model with evidence from diverse international cases.
    PLoS One. 2026;21:e0339304.
    

    >> Share

    
    

    
    Science

19. COHEN J
    Scientists reject call to retest childhood vaccines.
    Science. 2026;391:220-221.
    

    >> Share

    
    

    
    Vaccine

20. MALLET A, Jaunay LB, Jaury P, Partouche H, et al
    Vaccine refusal during the COVID-19 pandemic: A qualitative study.
    Vaccine. 2026;74:128206.
    

    >> Share

    
    
21. HEBERT LS, Pickens W, Satterwhite E, Soto GB, et al
    Erratum to "Gene discovery and expression analysis of the B cell receptor repertoire in the domestic ferret model" [Vaccine 64 (2025) 127725].
    Vaccine. 2026;74:128161.
    

    >> Share

    
    
22. FAY MJ, Howe AS, Wilson E, Sinclair O, et al
    Impact of a single-dose program on varicella hospitalizations and infectious disease inequity in New Zealand: A retrospective cohort study.
    Vaccine. 2026;72:128082.
    

    >> Share

    
    
23. CATA-PRETA BO, Arroyave L, Costa FS, Mengistu T, et al
    Monitoring the SDG immunization indicator: Approaches and challenges.
    Vaccine. 2026;72:128118.
    

    >> Share

    
    
24. DRISLANE S, Moore H, Attwell K
    Understanding parental decisions to decline or delay infant RSV immunisation, nirsevimab, in Western Australia in 2024.
    Vaccine. 2026;72:128133.
    

    >> Share

    
    
25. SINCLAIR JE, Mayfield HJ, Lu H, Brown SJ, et al
    Estimating risk of long COVID using a Bayesian network-based decision support tool.
    Vaccine. 2026;72:128127.
    

    >> Share

    
    
26. JABBAR F, Kadhim KA, Alhilfi RA, Al Khafaji IS, et al
    Advancements in monitoring adverse events following immunization in Iraq: Insights from the CIVIE project 2022-2023.
    Vaccine. 2026;72:128121.
    

    >> Share

    
    
27. ZINTGRAFF J, Gagetti P, Eluchans NS, Marchetti P, et al
    Serotype distribution and antimicrobial resistance in pediatric invasive pneumococcal pneumonia: A Laboratory Surveillance Study from Argentina, 2022-2024.
    Vaccine. 2026;72:128128.
    

    >> Share

    
    
28. TIPTON T, Laidlaw S, Nguyen D, Longet S, et al
    ACE2 inhibition ELISA is an effective surrogate for SARS-CoV-2 live virus neutralisation.
    Vaccine. 2026;72:128123.
    

    >> Share

    
    
29. DE OLIVEIRA NR, Maia MAC, Bunde TT, Pedra ACK, et al
    A self-assembled Pirococcus abyssi exosome complex displaying outer membrane proteins of Leptospira interrogans elicits protective immunity against leptospirosis.
    Vaccine. 2026;73:128159.
    

    >> Share

    
    
30. DAS S, Begum F, Ghora S, Ray U, et al
    Engineered dengue virus NS1 mRNA-lipid nanoparticle induces therapeutic IgG production that lacks autoantibody activity and neutralizes NS1 entry in liver cells.
    Vaccine. 2026;73:128147.
    

    >> Share

    
    
31. TYAGI P, Ganguly M, Manney S, Wadkar K, et al
    Plaque reduction neutralization test (PRNT(50)) for the detection of anti-yellow fever antibodies from clinical samples.
    Vaccine. 2026;73:128151.
    

    >> Share

    
    
32. SETHNA V, Apte A, Sanghavi S, Tang Y, et al
    Nasopharyngeal pneumococcal carriage in Indian children following 10-valent PCV (PNEUMOSIL(R)) introduction through India's universal immunization program: A post licensure cross-sectional study.
    Vaccine. 2026;73:128129.
    

    >> Share

    
    
33. HARKER EJ, Lewis NM, Johnson CA, Zhu Y, et al
    Differences in influenza vaccine effectiveness by sex among adults hospitalized with acute respiratory illness-IVY network, January 24, 2022-September 1, 2024.
    Vaccine. 2026;74:128192.
    

    >> Share

    
    
34. SABIR R, Liu M, Saeed HA, Deng Z, et al
    Next-generation live vector vaccine targeting Mycoplasma synoviae and Mycoplasma gallisepticum via recombinant Salmonella.
    Vaccine. 2026;74:128211.
    

    >> Share

    
    
35. SHENG S, Sun Y, Qin J, Zhao J, et al
    Hepatitis B core antigen-based trivalent VLP vaccine against porcine viral diarrhea.
    Vaccine. 2026;74:128210.
    

    >> Share

    
    
36. PAGE CL, Holbrook BC, Miller LD, Grayson JM, et al
    TLR5 versus TLR7/8 agonist-dependent modulation of the early gene expression response to inactivated influenza virus vaccine in newborn nonhuman primates.
    Vaccine. 2026;74:128163.
    

    >> Share

    
    
37. DE MORAES JC, Ribeiro KB, Vargas-Zambrano JC, Rujula MJP, et al
    Parental perceptions of adverse events associated with the whole-cell pertussis vaccine in Brazil.
    Vaccine. 2026;74:128184.
    

    >> Share

    
    
38. COBLENTZ EG, Packee CR, Ky SL, Brubaker AG, et al
    Prioritization of HPV vaccine preventable diseases among emerging adults - Implications for health education and communication.
    Vaccine. 2026;74:128223.
    

    >> Share

    
    
39. LU Y, Zhao W, Xu S, Tang C, et al
    Effectiveness of information interventions in reducing HPV vaccine hesitancy: a randomized survey experiment in China.
    Vaccine. 2026;74:128205.
    

    >> Share

    
    
40. CHENG K, Pullenayegum E, Singh P, Loeb M, et al
    Use of composite outcomes in cluster randomized control trials of influenza vaccines.
    Vaccine. 2026;74:128224.
    

    >> Share

    
    
41. VEERARAGHAVAN B, Varghese R, Gurumoorthy M
    Beyond serotypes: Why GPSC10 redefines vaccine escape in the pneumococcal vaccine era.
    Vaccine. 2026;74:128238.
    

    >> Share

    
    
42. PATERNINA-DE LA OSSA R, Oliveira MC, Achcar JA, Zanin-Silva DC, et al
    Immunological responses to tetanus, diphtheria, pertussis (Tdap) vaccine in Brazilian hematopoietic stem cell transplant recipients.
    Vaccine. 2026;75:128250.
    

    >> Share

    
    
43. DE WALS P, Papenburg J, Gilca R, Brousseau N, et al
    Are hemagglutinin-only influenza vaccines as effective as conventional influenza vaccines against severe infection?
    Vaccine. 2026;74:128234.
    

    >> Share

    
    

    
    Virology

44. THOMAS MH, Carlock MA, Ross TM
    Adjuvants enhance protective antibodies against seasonal influenza viruses following a single vaccination of Fluzone.
    Virology. 2026;616:110787.
    

    >> Share

    
    

    
    Virus Res

45. NAZKI S, Reine J, Kailath R, Gilbert S, et al
    Replication-incompetent viral vaccine vectors ChAdOx1 and MVA as tools for evaluating T-cell responses to naturally processed antigens in vitro.
    Virus Res. 2026;364:199691.
    

    >> Share

    
    
46. NGUYEN TTN, Tun MMN, Vu TBH, Nguyen TTT, et al
    Implications of Immune Responses to DENV, JEV, and ZIKV Infections for Cross-Reactivity and Considerations for Vaccine Evaluation.
    Virus Res. 2026 Jan 8:199689. doi: 10.1016/j.virusres.2026.199689.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share